New combo aims to stall ovarian Cancer's return
NCT ID NCT04387227
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 41 times
Summary
This study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can delay or prevent ovarian, fallopian tube, or primary peritoneal cancer from coming back after a rise in CA-125 levels. It includes 22 adults whose cancer has returned but is not yet visible on scans. The goal is to see if this combination can slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.